Panacos Pharmaceuticals

Panacos is a Delaware Corporation founded in 1992. Panacos' scientific and clinical programs originated in anti-infective technologies designed to prevent the spread of infectious disease by blood transfusions. In March of 2005, Panacos merged with V.I. Technologies, Inc. (Vitex), a biotechnology company developing products designed to improve the safety of the world's blood supply. The merger with Panacos immediately expanded the Vitex pipeline into novel, high value therapeutics. The Panacos team that joined Vitex is recognized for fundamental contributions to HIV biology and drug development. The combined company has a strong intellectual property position and the potential to accomplish significant near term milestones to create value from our promising pipeline.The corporate headquarters for Panacos is in Watertown, Massachusetts. The Company has an R&D facility in Gaithersburg, Maryland, focused on the discovery and development of novel therapeutics for HIV and other serious viral diseases. Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos’ lead candidate, bevirimat (PA-457), is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. By targeting a novel step in the virus life cycle, maturation inhibitors are designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. Drug resistance is the most pressing problem in HIV therapy and the leading cause of treatment failure. Panacos' proprietary discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.

Contact Details: 134 Coolidge Avenue Watertown Massachusetts 02472 United States of America Tel: (617) 926-1551 Fax: (617) 923-2245 Email: info@panacos.com WWW: www.panacos.com/

Loading...

Recent Publications by Panacos Pharmaceuticals:
Elevated temperature triggers human respiratory syncytial virus F protein six-helix bundle formation. Human respiratory syncytial virus (RSV) is a major cause of severe lower...	20th November, 2009	Panacos Pharmaceuticals, Inc., 209 Perry Parkway, Suite 7, Gaithersburg,	Virology. 2009 Nov 16. DOI Direct Link
Pharmacokinetic properties and tolerability of bevirimat and atazanavir in healthy volunteers: an open-label, parallel-group study. BACKGROUND: Bevirimat, an inhibitor of HIV-1 maturation, is currently in...	10th February, 2009	Panacos Pharmaceuticals Inc., Gaithersburg, Maryland 20877, USA.	Clin Ther. 2008 Oct;30(10):1794-805. DOI Direct Link
Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Existing antiretroviral treatments for HIV type-1 (HIV-1) disease are...	17th December, 2008	Panacos Pharmaceuticals,	Antivir Chem Chemother. 2008;19(3):107-13.
The absorption, distribution, metabolism and elimination of bevirimat in rats. Bevirimat is the first drug in the class of maturation inhibitors, which...	19th November, 2008	Panacos Pharmaceuticals, Inc., 209 Perry Parkway, Unit 7, Gaithersburg MD	Biopharm Drug Dispos. 2008 Oct;29(7):396-405. DOI Direct Link
Safety and pharmacokinetics of Bevirimat (PA-457), a novel inhibitor of human immunodeficiency virus maturation, in healthy volunteers. Bevirimat (BVM; formerly known as PA-457) is a novel inhibitor of human...	9th January, 2008	Drug Development, Panacos Pharmaceuticals, 209 Perry Parkway, Suite 7,	Antimicrob Agents Chemother. 2007 Sep;51(9):3063-6. Epub 2007 Jun 18. DOI Direct Link
→View more Panacos Pharmaceuticals research publications.

Press Releases on Panacos Pharmaceuticals:
New Report from PharmaPlus: HIV Pipelines & Deals	1st December, 2003	Pharmaplus	New Report from PharmaPlus: HIV Pipelines & Deals  At the end of November 2003 the joint United Nations Program on HIV/AIDS and the World Health Organization presented

BioNews Results for Panacos Pharmaceuticals:
Panacos Pharmaceuticals Inc.-Deals & Alliances Report - research report released	PR inside:  Oct 29 2009 5:45PM Matching: panacos pharmaceuticals
Panacos Pharmaceuticals Inc-Therapeutic Competitors - research report released	PR inside:  Oct 28 2009 9:26AM Matching: panacos pharmaceuticals
Biotech Mailbag: Myriad Pharma	TheStreet.com:  Sep 25 2009 12:56PM Matching: panacos pharmaceuticals

Panacos Pharmaceuticals Patents:
US Patent No.	Title
7537765	Inhibition of HIV-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein
7365221	Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
7311916	Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41
6768007	Substituted 3',4'-di-O-camphanoyl-(+)-cis-khellactone analogs, compositions thereof, and methods for using thereof
6605427	Assay for detection of viral fusion inhibitors
→View more Panacos Pharmaceuticals patents.

Panacos Pharmaceuticals (PANC) Financial information Links from Barchart
PANC Quote from from Barchart.com
PANC Chart from from Barchart.com
PANC Profile from from Barchart.com
PANC Opinion from from Barchart.com
→View more Panacos Pharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 363 times since April 2007, the link to the organisation's website has been followed 55 times

Search for more companies in Watertown

Search for more companies in Massachusetts

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Panacos Pharmaceuticals